Literature DB >> 2239274

Neurosecretory dysfunction of growth hormone secretion in thalassemia major.

N Shehadeh1, A Hazani, M C Rudolf, I Peleg, A Benderly, Z Hochberg.   

Abstract

The growth retardation of children with thalassemia major is multifactorial. Along the endocrine axis of growth hormone (GH), serum somatomedin has been shown to be deficient and GH response to GH-releasing hormone impaired, while GH response to provocative stimuli is normal. We studied the spontaneous secretion of GH in seven patients with thalassemia major and growth retardation. Three of the patients were hypothyroid, and the other four were euthyroid. Spontaneous secretion of GH in all seven patients was subnormal: the number of pulses, the mean pulse amplitude, and the integrated concentration of GH were all lower than in 14 age- and sex-matched (10 pubertal and 4 prepubertal) control subjects. GH response to provocative stimuli was normal in the euthyroid patients. This pattern of response corresponds with the definition of neurosecretory dysfunction of GH secretion. It is concluded that the growth retardation of patients with thalassemia major is partly due to neurosecretory dysfunction of GH secretion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2239274     DOI: 10.1111/j.1651-2227.1990.tb11556.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  15 in total

Review 1.  Endocrine complications of thalassemia.

Authors:  D Tiosano; Z Hochberg
Journal:  J Endocrinol Invest       Date:  2001-10       Impact factor: 4.256

2.  Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis.

Authors:  A Lasco; N Morabito; A Gaudio; A Crisafulli; A Meo; G Denuzzo; N Frisina
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

Review 3.  Growth and endocrine function in thalassemia major in childhood and adolescence.

Authors:  M Delvecchio; L Cavallo
Journal:  J Endocrinol Invest       Date:  2010-01       Impact factor: 4.256

Review 4.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

5.  Evaluation of hypothalamic-pituitary function in patients with thalassemia major.

Authors:  L Danesi; M Scacchi; M De Martin; A Dubini; P Massaro; A T Majolo; F Cavagnini; E E Polli
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

Review 6.  Growth of children with beta-thalassemia major.

Authors:  Louis Ck Low
Journal:  Indian J Pediatr       Date:  2005-02       Impact factor: 1.967

7.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2020-05-28

8.  Osteoporosis syndrome in thalassaemia major: an overview.

Authors:  Meropi Toumba; Nicos Skordis
Journal:  J Osteoporos       Date:  2010-05-26

9.  Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major.

Authors:  R G Grundy; K A Woods; M O Savage; J P Evans
Journal:  Arch Dis Child       Date:  1994-08       Impact factor: 3.791

10.  Growth hormone reserve in adult beta thalassemia patients.

Authors:  Guy Vidergor; Ada W Goldfarb; Benjamin Glaser; Rivka Dresner-Pollak
Journal:  Endocrine       Date:  2007-02       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.